Changes in COPD demographics and costs over 20 years.

  title={Changes in COPD demographics and costs over 20 years.},
  author={Christopher M. Blanchette and Anand A. Dalal and Douglas W. Mapel},
  journal={Journal of medical economics},
  volume={15 6},
OBJECTIVE Chronic obstructive pulmonary disease (COPD) is now the third leading cause of death in the US and responsible for significant healthcare resource use. The purpose of this study was to examine the changes in COPD costs over 20 years and assess total direct cost trends over the last 10. METHODS A cross-sectional study of a population-based survey (2007 Medical Expenditure Panel Survey compared to the 1987 National Medical Expenditures Panel Survey) of respondents aged 40 and older… CONTINUE READING
12 Citations
11 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 11 references

Cost-effectiveness of combination fluticasone propionate/salmeterol 250/50 mcg versus salmeterol in severe COPD patients

  • AA Dalal, M St. Charles, HV Petersen
  • 2012

Morbidity and mortality chart book on cardiovascular, lung and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health

  • National Heart, Lung, Blood Institute
  • 2009

Validity of pharmacoepidemiologic drug and diagnosis data

  • A West, BL Strom, C. Poole
  • Strom BL, Pharmacoepidemiology,
  • 2005

How to score version 2 of the SF-12 Health Survey (with a supplement documenting version

  • JE Ware, M Kosinski, DM Turner-Bowker
  • QualityMetric Incorporated,
  • 2002

Similar Papers

Loading similar papers…